

# CITATION REPORT

List of articles citing

## Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

DOI: 10.1038/leu.2015.356  
Leukemia, 2016, 30, 1005-17.

**Source:** <https://exaly.com/paper-pdf/65669030/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
191	Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. <b>2016</b> , 9, 6037-6048		11
190	Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. <i>Blood</i> , <b>2016</b> , 128, 2757-2764	56	
189	Primary Plasma Cell Leukemia: Identity Card 2016. <b>2016</b> , 17, 19		13
188	Multiple myeloma in the marrow: pathogenesis and treatments. <b>2016</b> , 1364, 32-51		83
187	Safety of proteasome inhibitors for treatment of multiple myeloma. <b>2017</b> , 16, 167-183		29
186	Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review. <b>2016</b> , 6, 27361		7
185	Developments in the Field of Myeloma in the Last Decade. <b>2017</b> , 33, 3-7		2
184	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. <b>2017</b> , 23, 930-937		8
183	Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. <b>2017</b> , 30, 843-853		7
182	The Value of Anti-Angiogenics in Multiple Myeloma Therapy. <b>2017</b> , 1-19		
181	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2017</b> , 28, iv52-iv61		426
180	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. <b>2017</b> , 98, 289-295		2
179	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <b>2017</b> , 99, 199-206		15
178	Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 198-218	4.5	33
177	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. <b>2017</b> , 18, 1061-1079		3
176	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <b>2017</b> , 4, e283-e292		13
175	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 457-466	4.5	100

174	Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation. <b>2017</b> , 23, 684-690		19
173	Effects of time delays in a mathematical bone model. <b>2017</b> , 26, 030503		10
172	Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?. <b>2017</b> , 5, 875-887		1
171	INSIDE INDUSTRY. <i>Asia Pacific Biotech News</i> , <b>2017</b> , 21, 38-49	0	
170	Chimeric antigen receptor T-cell therapies for multiple myeloma. <i>Blood</i> , <b>2017</b> , 130, 2594-2602	2.2	128
169	MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients. <b>2017</b> , 95, 743-748		3
168	How I treat myeloma with new agents. <i>Blood</i> , <b>2017</b> , 130, 1507-1513	2.2	53
167	How I treat first relapse of myeloma. <i>Blood</i> , <b>2017</b> , 130, 963-973	2.2	49
166	New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials. <i>Leukemia</i> , <b>2017</b> , 31, 1843-1844	10.7	
165	Safety of ixazomib for the treatment of multiple myeloma. <b>2017</b> , 16, 973-980		14
164	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. <b>2017</b> , 101, 81-88		25
163	Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 797-808	1.9	4
162	Decision Aids: Assisting Patients With Multiple Myeloma and Caregivers With Treatment Decision Making. <i>Clinical Journal of Oncology Nursing</i> , <b>2017</b> , 21, 660-664	1.1	0
161	Management of multiple myeloma in the relapsed/refractory patient. <b>2017</b> , 2017, 508-517		43
160	New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. <b>2017</b> , 8, 107-121		17
159	Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. <b>2017</b> , 8, 1801-1808		4
158	Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. <b>2017</b> , 11, 2399-2408		23
157	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. <i>Blood Advances</i> , <b>2017</b> , 1, 455-466	7.8	43

156	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. <b>2018</b> , 8, 4159		51
155	The multiple myelomas - current concepts in cytogenetic classification and therapy. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 409-421	19.4	121
154	Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. <b>2018</b> , 200, 3485-3494		16
153	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. <b>2018</b> , 73-96		1
152	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2305-2317	1.9	9
151	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. <b>2018</b> , 24, 1372-1378		17
150	Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. <b>2018</b> , 107, 541-550		10
149	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. <i>Future Oncology</i> , <b>2018</b> , 14, 1035-1047	3.6	56
148	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <b>2018</b> , 121, 74-89		15
147	Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF- $\kappa$ B activity and increases drug resistance in multiple myeloma. <b>2018</b> , 293, 2452-2465		16
146	Therapy sequencing strategies in multiple myeloma: who, what and why?. <i>Future Oncology</i> , <b>2018</b> , 14, 95-99	3.6	4
145	Going the distance: Are we losing patients along the multiple myeloma treatment pathway?. <b>2018</b> , 126, 19-23		6
144	Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. <b>2018</b> , 26, 2075-2090		15
143	Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. <b>2018</b> , 24, 406-409		14
142	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. <b>2018</b> , 78, 19-37		70
141	T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. <b>2018</b> , 36, 2267-2280		375
140	Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment. <b>2018</b> , 13, 373		12
139	PharmaForum BMS. <b>2018</b> , 41, 790-791		

138	Ixazomib for the treatment of multiple myeloma. <b>2018</b> , 19, 1949-1968		32
137	Special problems in the management of elderly patients with multiple myeloma. <b>2018</b> , 58, 64-69		
136	Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. <b>2018</b> , 11, 128		24
135	The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma. <b>2018</b> , 15, 5387-5396		5
134	A look at treatment strategies for relapsed multiple myeloma. <b>2018</b> , 18, 735-750		1
133	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. <b>2018</b> , 97, 1671-1682		7
132	Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. <b>2018</b> , 17, 985-996		11
131	Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma. <b>2018</b> , 15, 4139-4147		6
130	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. <b>2018</b> , 19, 169		4
129	Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse. <b>2018</b> , 11, 7		6
128	Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting. <b>2018</b> , 75, 1824-1830		2
127	A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 350-353	4.5	2
126	Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1132-1140	7.1	13
125	Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	4
124	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 439-445	7.1	5
123	The therapeutic role of natural killer cells in multiple myeloma. <b>2019</b> , 2, e49		1
122	Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 11-24	4.5	12
121	Multiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging. <b>2019</b> , 191, 998-1009		10

120	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 522-530.e1	2	28
119	Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 585-592.e1	2	0
118	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. <b>2019</b> , 14, 187-196		6
117	Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. <b>2019</b> , 19, 73-92		58
116	MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. <b>2019</b> , 9, 249		14
115	Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 38	7	37
114	Evaluation of the safety and efficacy of daratumumab outside of clinical trials. <b>2019</b> , 109, 665-672		11
113	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. <b>2019</b> , 37, 1617-1628		12
112	Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma. <b>2019</b> , 43, 1028-1034		2
111	New proteasome inhibitors in the treatment of multiple myeloma. <b>2019</b> , 41, 76-83		18
110	Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma. <b>2019</b> , 55, 25-30		1
109	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , <b>2019</b> , 3, 4095-4103	7.8	9
108	Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 603-611	7.8	6
107	Monoclonal antibody utilization characteristics in patients with multiple myeloma. <b>2019</b> , 30, 859-865		2
106	Elotuzumab-Triplette - Verdopplung des progressionsfreien Berlebens. <b>2019</b> , 42, 692-693		
105	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 29-34	2	41
104	[First-line treatment of multiple myeloma]. <b>2019</b> , 60, 23-33		0
103	Navigating the treatment landscape in multiple myeloma: which combinations to use and when?. <b>2019</b> , 98, 1-18		40

102	Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2085-2087	1.9	2
101	Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 222-225	1.9	7
100	Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. <b>2020</b> , 55, 419-430		5
99	Treatment of relapsed multiple myeloma: Evidence-based recommendations. <b>2020</b> , 39, 100616		29
98	How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. <b>2020</b> , 29, 1419-1431		8
97	Limited treatment options in refractory multiple myeloma: promising therapeutic developments. <b>2020</b> , 20, 31-44		3
96	Multiple myeloma current treatment algorithms. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 94	7	59
95	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
94	Treatment of relapsed, refractory multiple myeloma: focus on new drugs. <b>2020</b> , 42, 2-3		
93	Prognostic Factors for Postrelapse Survival after ex Vivo CD34-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. <b>2020</b> , 26, 2040-2046		1
92	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1630-1642	21.7	110
91	Fluorodeoxyglucose-avid focal lesions and extramedullary disease on 18F-FDG PET/computed tomography predict the outcomes of newly diagnosed symptomatic multiple myeloma patients. <i>Nuclear Medicine Communications</i> , <b>2020</b> , 41, 950-958	1.6	1
90	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , <b>2020</b> , 34, 3298-3309	10.7	23
89	Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 1453-1464	6.6	8
88	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 35	7	10
87	CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. <i>Blood</i> , <b>2020</b> , 136, 2416-2427	2.2	32
86	Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
85	SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation. <i>Life Sciences</i> , <b>2020</b> , 256, 117971	6.8	7

84	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	11
83	The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple Myeloma. <i>Acta Haematologica</i> , <b>2020</b> , 143, 516-517	2.7	0
82	Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. <i>Value in Health</i> , <b>2020</b> , 23, 441-450	3.3	5
81	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1850-1859	1.9	4
80	Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, e212-e219	2	1
79	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. <i>Leukemia</i> , <b>2021</b> , 35, 1732-1744	10.7	3
78	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , <b>2021</b> , 137, 1154-1165	2.2	18
77	Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 521-530	3.6	5
76	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 142-154	21.7	22
75	CAR T cell therapies for patients with multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 71-84	19.4	61
74	Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , <b>2021</b> , 36, e55	4.7	1
73	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , <b>2021</b> , 58, 45-55	4	6
72	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. <i>Clinical Hematology International</i> , <b>2021</b> , 3, 27-33	1.8	
71	A clinical perspective on plasma cell leukemia; current status and future directions. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 23	7	8
70	Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management. <i>Tumori</i> , <b>2021</b> , 107, NP37-NP40	1.7	3
69	Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 1078155221995532	1.7	
68	Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 44	7	
67	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. <i>Blood Advances</i> , <b>2021</b> , 5, 1340-1343	7.8	2



66	When and How to Treat Relapsed Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2021</b> , 41, 358-375	7.1	3
65	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , <b>2021</b> , 22, e105-e118	21.7	32
64	Current approaches to management of high-risk multiple myeloma. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 854-871	7.1	8
63	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , <b>2021</b> , 104, 106576	2.7	10
62	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 3526-3533	10.7	5
61	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 580-586	4.5	1
60	Plasmacytoma and plasma cell myeloma affecting the jaws: A multi-institutional collaborative study. <i>Journal of Oral Pathology and Medicine</i> , <b>2021</b> , 50, 613-621	3.3	
59	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , <b>2021</b> , 127, 3413-3421	6.4	0
58	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , <b>2021</b> , 17, 1987-2003	3.6	8
57	LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/ $\beta$ -catenin/cyclin D1 signaling via PLAGL2. <i>Cell Biology and Toxicology</i> , <b>2021</b> , 1	7.4	6
56	Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
55	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
54	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , <b>2021</b> , 17, 4797-4812	3.6	1
53	Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1554-1562	7.1	0
52	Epidemiology, Staging, and Management of Multiple Myeloma. <i>Medical Sciences (Basel, Switzerland)</i> , <b>2021</b> , 9,	3.3	13
51	Multiple Myeloma. <b>2020</b> , 61-95		1
50	Onkologika. <b>2017</b> , 597-639		1
49	Myelosuppression, Bone Disease, and Acute Renal Failure: Evidence-Based Recommendations for Oncologic Emergencies. <i>Clinical Journal of Oncology Nursing</i> , <b>2017</b> , 21, 60-76	1.1	6

48	[Current approaches to treating of patients with multiple myeloma with renal failure: Questions and proofs]. <i>Terapevticheski Arkhiv</i> , <b>2017</b> , 89, 112-117	0.9	3
47	Cold atmospheric plasma as a potential tool for multiple myeloma treatment. <i>Oncotarget</i> , <b>2018</b> , 9, 18002-18017	3.3	6
46	The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma. <i>Oncotarget</i> , <b>2020</b> , 11, 1576-1589	6.6	10
45	Identification of PIKfyve kinase as a target in multiple myeloma. <i>Haematologica</i> , <b>2020</b> , 105, 1641-1649	1.4	9
44	Treatment of relapsed and refractory multiple myeloma. <i>Blood Research</i> , <b>2020</b> , 55, S43-S53	2	
43	Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMA Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> ,	0.4	
42	Stem Cell Transplantation for Multiple Myeloma. <i>Pancreatic Islet Biology</i> , <b>2017</b> , 73-86	0	
41	Advocacies in Support of Rare Disease Patients (Vol. 21, No. 6, Full Issue). <i>Asia Pacific Biotech News</i> , <b>2017</b> , 21,	0.1	
40	Optimising Treatment in Relapsed, Refractory Multiple Myeloma. <i>European Oncology and Haematology</i> , <b>2018</b> , 14, 96		1
39	Onkologika. <b>2018</b> , 645-691		
38	Onkologika. <b>2019</b> , 817-875		
37	The Value of Anti-angiogenics in Multiple Myeloma Therapy. <b>2019</b> , 639-658		
36	Onkologika. <b>2020</b> , 671-732		1
35	Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2021</b> , 13, e2021012	3.2	2
34	Huanglian Jiedu Decoction for treatment of multiple myeloma: A protocol for a systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2020</b> , 99, e22378	1.8	2
33	Health-related quality of life in multiple myeloma in Kurdistan Iraq. <i>Iraqi Journal of Hematology</i> , <b>2020</b> , 9, 101	0.1	
32	Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISM. <i>Cancer Science</i> , <b>2020</b> , 111, 2116-2122	6.9	3
31	Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma. <i>Oncogematologiya</i> , <b>2020</b> , 15, 29-41	0.3	1

30	[Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2017</b> , 38, 487-493	0.4	
29	[The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2021</b> , 42, 628-634	0.4	
28	Treatment for multiple myeloma in hospital at home: clinical characteristics and patient care pathways.. <i>Home Health Care Services Quarterly</i> , <b>2022</b> , 1-17	1.9	0
27	Prognostic value of F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis.. <i>Clinical and Experimental Medicine</i> , <b>2022</b> , 1	4.9	
26	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2022</b> ,	2	
25	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2022</b> ,	2	0
24	Phase II trial of allogeneic transplantation plus novel drugs in multiple myeloma: effect of intensifying reduced intensity conditioning with bortezomib and adding maintenance treatment.. <i>Transplantation and Cellular Therapy</i> , <b>2022</b> ,		1
23	CT-derived relationship between low relative muscle mass and bone damage in patients with multiple myeloma undergoing stem cells transplantation.. <i>British Journal of Radiology</i> , <b>2021</b> , 20210923	3.4	1
22	Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 1-9	2.2	
21	Image_1.JPEG. <b>2019</b> ,		
20	Image_2.JPEG. <b>2019</b> ,		
19	Image_3.JPEG. <b>2019</b> ,		
18	Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.. <i>Hematological Oncology</i> , <b>2022</b> ,	1.3	1
17	Patient and Caregiver Experience Decision Factors in Treatment Decision MakingResults of a Systematic Literature Review of Multiple Myeloma Decision Aids. <i>Value in Health</i> , <b>2022</b> ,	3.3	
16	Oncohematology. <b>2022</b> , 365-407		
15	Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance. <b>12</b> ,		
14	Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy. <b>2022</b> , 122, 106949		0
13	Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab. <b>2022</b> , 21, 153303382211065		1

- 12 Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909). ○
- 11 Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting. **2022**, 11, ○
- 10 BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. **2022**, 215949 ○
- 9 Real-world evidence in diagnostics and treatment of patients with multiple myeloma. **2022**, 75, 115-120 ○
- 8 Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. ○
- 7 Multiple Myeloma. **2022**, 159-175 ○
- 6 Management of Relapsed and Refractory Multiple Myeloma: Recent advances. **2022**, 43, 458-472 ○
- 5 HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. **2022**, 17, e0274704 ○
- 4 Efficacy and Safety Analysis of VRD-PDCE in Treatment-Native Patients with Multiple Extramedullary Plasmacytomas or Plasma Cell Leukemia. ○
- 3 Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. **2023**, 15, 532 ○
- 2 AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. **2023**, 15, 477 ○
- 1 A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway. **2023**, 55, 215-224 ○